Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Antipsychotics in the general population and the driver population

comparisons from a population-based registry study

Herrera-Gómez, Franciscoa,,b; Gutierrez-Abejón, Eduardoc; Álvarez, F. Javiera,,d

International Clinical Psychopharmacology: July 2019 - Volume 34 - Issue 4 - p 184–188
doi: 10.1097/YIC.0000000000000263
Short Communication
Buy
SDC

Antipsychotics are considered driving-impairing medicines. A population-based registry study design was conceived to assess the year-2016 antipsychotic dispensation in Castile and León, Spain. Weighting was performed to obtain the adjusted antipsychotic consumption for licensed drivers according to age and gender using the Spanish national drivers’ license census data. In 2016, antipsychotics were dispensed to 3.86% of the general population and 2.71% of licensed drivers. Antipsychotic use was higher in females (4.72%) than in males (2.98%), and increased as age increased, but women drivers used less antipsychotics after 60 years old. Chronic antipsychotic use (≥30 days) accounted for 1.62%. Typical antipsychotics predominated among acute users (1.60% versus 0.09%), while atypical antipsychotics were the rule in chronic use (1.41% versus 0.36%). A concomitant use of antipsychotics with other driving-impairing medicines was also common. This study is intended for updating the epidemiological knowledge of all involved in the control of use of antipsychotics and other driving-impairing medicines (healthcare providers, patients, authorities, and drug developers) in order to improve prescribing/dispensing and a well tolerated use of all driving-impairing medicines by the population. Awareness is needed to improve safety on driving, and there is a need worldwide to improve interventions in the field of medicines and driving.

aPharmacology and Therapeutics, Faculty of Medicine, University of Valladolid, Valladolid

bNephrology, Hospital Virgen de la Concha – Sanidad de Castilla y León, Zamora

cTechnical Direction of Pharmaceutical Assistance, Gerencia Regional de Salud de Castilla y León

dCEIm, Hospital Clínico Universitario de Valladolid – Sanidad de Castilla y León, Valladolid, Spain.

Received 28 November 2018 Accepted 28 March 2019

Supplemental Digital Content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal’s website, www.intclinpsychopharm.com.

a CONCYLIA. Sistema de Información de Farmacia. Gerencia Regional de Salud de Castilla y León. http://www.saludcastillayleon.es/portalmedicamento/es/indicadores-informes/concylia [Accessed 5 September 2018].

b Ministerio del Interior. Dirección General de Tráfico. Estadísticas e Indicadores. Permisos de conducción/[Driving licenses]. http://www.dgt.es/es/seguridad-vial/estadisticas-e-indicadores/permisos-conduccion/ [Accessed 5 September 2018].

Correspondence to Francisco Herrera-Gómez, MD, PhD, Pharmacology and Therapeutics, Faculty of Medicine, University of Valladolid, Valladolid, Spain, Tel: +34 983423077; e-mail: fherrera@med.uva.es

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.